Certified Responsible AI Governance & Ethics (CRAGE): 612-51 Exam Premium File as PDF & Test Engine

A large enterprise is expanding its AI capabilities from one successful pilot into several business functions.
To govern this expansion responsibly, leadership creates a structure in which enterprise-wide standards for governance, architecture, platforms, and ethical oversight are maintained centrally. Meanwhile, individual departments receive designated representatives who adapt AI solutions to local workflows, coordinate adoption activities, and serve as liaisons between central oversight and operational teams. This approach is intended to balance department-level innovation with organization-wide consistency, interoperability, and compliance, preventing fragmented AI adoption while enabling scalable growth.
Which AI scaling strategy is being used in this scenario to support coordinated, enterprise-wide deployment while preserving governance consistency?

• A. Interoperability enablement
• B. Continuous model refinement
• C. Hub-and-spoke model
• D. Phased expansion

Horizon Defense is deploying an AI system to monitor satellite imagery for early threat detection in a classified operational setting. During a red-team exercise required by the defense oversight board, analysts show that carefully crafted, imperceptible changes to incoming image data can make the model misclassify benign assets as hostile military equipment. The manipulation does not affect human analyst review, but it consistently circumvents automated AI-based alerting thresholds, creating concerns about escalation errors, false positives, and operational decision-making risk. As the Chief AI Risk Officer, you must categorize this vulnerability to identify appropriate mitigation controls and assurance requirements.
Which AI-specific threat is chiefly exploited in this scenario?

• A. Model Extraction
• B. Dataset Poisoning
• C. Model Poisoning
• D. Adversarial Manipulation

A multinational pharmaceutical company is establishing oversight for an AI-driven drug-discovery platform that will affect clinical-trial design and candidate prioritization across multiple regions. Although the initial deployment centers on predictive modeling, leadership expects future phases to include foundation models, automated hypothesis generation, and cross-domain AI systems across R & D, pharmacovigilance, and regulatory submissions. Senior executives seek to avoid fragmented oversight structures or repeatedly redesigning governance controls as these capabilities develop.
When assessing governance frameworks, which selection consideration ensures the long-term viability of oversight as the organization's AI use cases and technical approaches evolve?

• A. Assess Organizational Goals
• B. Evaluate the AI System's Impact
• C. Framework Flexibility and Scalability
• D. Consider Legal and Regulatory Obligations

A defense AI program finishes a full-cycle red-blue adversarial exercise. The red team identifies several vulnerabilities in model interpretability, audit logging, and validation repeatability. The blue team must now deliver an assurance report to executive leadership and mission owners. Leadership expects evidence that the organization is mission-ready, risk-aware, and compliant with emerging AI assurance standards.
Which reporting strategy most effectively demonstrates evaluative reasoning and constructive assurance planning in defensive AI operations?

• A. Submit a technical log summary describing individual red team findings with no linkage to mission priorities
• B. Produce an integrated assurance dossier mapping adversarial findings to mission objectives, prioritized remediation actions, and a phased testing roadmap
• C. Provide model accuracy benchmarks comparing baseline and post-patch performance
• D. Deliver a vendor attestation report confirming that AI validation followed contractual standards